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ABSTRACT
The ongoing Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks pose a worldwide public health threat.
Blocking MERS-CoV zoonotic transmission from dromedary camels, the animal reservoir, could potentially reduce the
number of primary human cases. Here we report MERS-CoV transmission from experimentally infected llamas to naïve
animals. Directly inoculated llamas shed virus for at least 6 days and could infect all in-contact naïve animals 4–5 days
after exposure. With the aim to block virus transmission, we examined the eﬃcacy of a recombinant spike S1-protein
vaccine. In contrast to naïve animals, in-contact vaccinated llamas did not shed infectious virus upon exposure to
directly inoculated llamas, consistent with the induction of strong virus neutralizing antibody responses. Our data
provide further evidence that vaccination of the reservoir host may impede MERS-CoV zoonotic transmission to humans.
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The Middle East respiratory syndrome coronavirus
(MERS-CoV) was ﬁrst identiﬁed in September 2012
[1]. This emerging zoonotic pathogen is associated
with severe pneumonia, acute respiratory distress syn-
drome, and multi-organ failure in humans resulting in
fatal outcomes. As of September of 2019, the World
Health Organization (WHO) has been notiﬁed of
2,458 laboratory-conﬁrmed cases in humans with at
least 848 deaths [2]. MERS-CoV cases have been
reported in 27 countries, mainly in the Middle East.
In addition, a major outbreak occurred in South
Korea in 2015 with 186 cases and 39 fatalities [3].
Therefore, MERS-CoV appears to be a current world-
wide public health threat.
The dromedary camel is the main reservoir for
MERS-CoV and plays a key role in the infection of pri-
mary human cases [4,5]. In New World
camelid species, MERS-CoV infection was evidenced
by the presence of MERS-CoV neutralizing antibodies
(NAbs) [6,7]. Furthermore, MERS-CoV experimental
infections in alpacas and llamas conﬁrmed that both
could serve as potential reservoirs [8–10].
Due to the high human lethality rates and the
absence of MERS-CoV-licensed vaccines or
treatments, MERS-CoV has been prioritized for
research and product development in the WHO
R&D Blueprint for Action to Prevent Epidemics
[11,12]. The WHO has suggested animal vacci-
nation as the best strategy to control MERS-CoV
infections, since reduction of virus shedding can
potentially prevent both animal-to-animal and zoo-
notic transmissions, and might have a faster devel-
opment and licensing pathway compared to human
vaccination [11].
The current MERS-CoV vaccine candidates mainly
use the entire or sub regions of the spike (S) protein or
its coding gene. This virus surface structural glycoprotein
binds to the host receptor, dipeptidyl peptidase 4 (DPP4)
[13], through its S1 subunit and is therefore the target of
choice to raise Nabs [14,15]. The S1 subunit protein is
immunogenic and can induce both T-cell mediated and
NAb responses mainly directed towards the receptor
binding domain (RBD, also named as S1B domain)
[14,16]. Recently, we reported that although most
NAbs target the S1B domain, antibodies targeting the
S1 sialic acid binding domain (S1A domain) can also pro-
vide protection against lethal MERS-CoV challenge in a
mouse model [17].
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONTACT Bart L. Haagmans b.haagmans@erasmusmc.nl Department of Viroscience, Erasmus Medical Centre, 3000 CA Rotterdam, The Netherlands;
Júlia Vergara-Alert julia.vergara@irta.cat IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la UAB, 08193 Bellaterra (Cer-
danyola del Vallès), Spain
*These authors contributed equally to this work.
Supplemental data for this article can be accessed https://doi.org/10.1080/22221751.2019.1685912
Emerging Microbes & Infections
2019, VOL. 8
https://doi.org/10.1080/22221751.2019.1685912
Several vaccine prototypes to control MERS-CoV
have been tested using a wide variety of delivery sys-
tems, including DNA vaccines, protein-based vaccines,
vector-based vaccines and live attenuated vaccines
[15,18]. Vector-based-vaccines have been developed
using the orthopox modiﬁed virus Ankara (MVA)
[19], diﬀerent host-origin adenovirus (AdV) [20–23],
measles virus (MeV) [24], rabies virus (RABV) [25],
and Venezuelan equine encephalitis replicons (VRP)
[22,26], all expressing diﬀerent lengths of the S protein.
These vector-based candidates were tested in human
DPP4 (hDPP4) transgenic or transduced mice, except
the orthopox-based recombinant vaccine, which
expresses the full-length MERS-CoV spike protein
and induced eﬃcient protective immunity in dromed-
aries [19]. Due to reticence in applying live genetically
modiﬁed organisms, protein recombinant subunit or
DNA vaccines mainly based on the S1 protein or
gene, respectively, are also under study. A DNA-
based vaccine expressing the full-length S protein was
shown to induce MERS-CoV speciﬁc NAbs and confer
protection in rhesus macaques [27]. In addition,
MERS-CoV protein-based vaccines using the full-
length or fragments of the S protein were produced
in the form of virus-like particles, nanoparticles, pep-
tides, or recombinant protein. Partial protection
eﬃcacy for some candidates has been demonstrated
in non-human primates (NHP) [28,29] and hDPP4
transgenic mice [30–36.] A more recent study demon-
strated that an S protein subunit vaccine conferred pro-
tection to MERS-CoV (EMC/2012 strain) in an alpaca
model, although in dromedary camels the vaccine was
only able to reduce and delay viral shedding [37]. How-
ever, there is no evidence that any of the MERS-CoV
vaccine candidates developed so far are able to block
MERS-CoV transmission in camelids when tested in
a direct-contact virus transmission setting, mimicking
natural transmission in the ﬁeld. Vaccinating the
MERS-CoV animal reservoirs can potentially reduce
transmission to humans and provide a simple and
economical solution to avoid expansion of this threa-
tening disease.
In the present study, we show eﬃcient MERS-CoV
transmission among llamas. Furthermore, we have suc-
cessfully used this direct-contact transmission model to
demonstrate the eﬃcacy of a recombinant S1-protein
vaccine, using a registered adjuvant, to block MERS-
CoV transmission.
Materials and methods
Animal welfare and ethics
Experiments with MERS-CoV were performed at the
Biosafety Level-3 (BSL-3) facilities of the Biocontain-
ment Unit of IRTA-CReSA (Barcelona, Spain). The
present study was approved by the Ethical and Animal
Welfare Committee of IRTA (CEEA-IRTA) and by the
Ethical Commission of Animal Experimentation of the
Autonomous Government of Catalonia (ﬁle No. FUE-
2017-00561265).
Cell culture and MERS-CoV
Vero cells were cultured in Dulbecco’s modiﬁed Eagle
medium, DMEM (Lonza) supplemented with 2%
fetal calf serum (FCS; EuroClone), 100 U/ml penicillin
(ThermoFisher Scientiﬁc, Life Technologies), 100 μg/
ml streptomycin (ThermoFisher Scientiﬁc, Life Tech-
nologies), and 2 mM glutamine (ThermoFisher Scien-
tiﬁc, Life Technologies). A passage 2 MERS-CoV
stock (Qatar15/2015 strain) was propagated in Vero
cells at 37°C in a CO2 incubator for 3 days. The infec-
tious virus titre was determined in Vero cells and cal-
culated by determining the dilution that caused
cytopathic eﬀect (CPE) in 50% of the inoculated cell
cultures (50% tissue culture infectious dose endpoint,
TCID50).
Vaccine
Full-length MERS-CoV S1 recombinant protein,
including A and B domains, was produced in house
using baculovirus and HEK 293 T cells production sys-
tems as previously described [17,38]. In brief, to pro-
duce soluble MERS-CoV S1 using the baculovirus
expression system, the gene fragment encoding the
MERS-CoV S1 subunit (amino acid 19–748; EMC/
2012 isolate; GenBank Accession YP_009047204.1)
was codon-optimized for insect cell expression and
cloned in-frame between honeybee melittin (HBM)
secretion signal peptide and a triple StrepTag puriﬁ-
cation tag in the pFastbac transfer vector. Generation
of bacmid DNA and recombinant baculovirus was per-
formed according to protocols from Bac-to-Bac system
(Invitrogen), and expression of MERS-CoV S1 was per-
formed by infection of recombinant baculovirus of Sf-9
cells. Recombinant proteins were harvested from cell
culture supernatants 3 days post infection and puriﬁed
using StrepTactin sepharose aﬃnity chromatography
(IBA).
Production of recombinant MERS-S1 in HEK 293 T
cells was described previously [17,38]. In brief, the
MERS-S1 (amino acid 1–747; EMC/2012 isolate; Gen-
Bank Accession YP_009047204.1) encoding sequence
was C-terminally fused to a gene fragment encoding
the Fc region of human IgG and cloned into the
pCAGGS mammalian expression vector, expressed by
plasmid transfection in HEK-293 T cells, and aﬃnity
puriﬁed from the culture supernatant using Protein-
A aﬃnity chromatography. The Fc part of S1-Fc fusion
protein was proteolytically removed by thrombin fol-
lowing Protein-A aﬃnity puriﬁcation using the throm-
bin cleavage site present at the S1-Fc junction.
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Animals, vaccination and experimental design
Sixteen healthy llamas were purchased and housed at
IRTA farm facilities at Alcarràs (Catalonia, Spain)
during the immunization period and transferred for
challenge at the BSL-3 animal facilities of the Biocon-
tainment Unit of IRTA-CReSA, in Barcelona (Spain).
Five llamas were prime vaccinated each with 35 µg
of a recombinant S1 protein produced in a baculovirus
system, emulsiﬁed (1:1 volume) with Montanide™ ISA
206 VG (Seppic) adjuvant and intramuscularly admi-
nistered (2 ml per animal and dose) in the right side
of the neck. A boosting immunization was conducted
3 weeks later as above (left side of the neck) but with
50 µg of recombinant S1 protein produced in HEK
293 T cells, emulsiﬁed (1:1 volume) with Montanide™
ISA 206 VG (Seppic) adjuvant. The correct structure of
the S1 antigens was previously conﬁrmed by reactivity
of conformational antibodies, DPP4 solid phase and
sialic acid binding assays [17]. Two weeks later,
MERS-CoV challenge was performed. The experiments
on virus transmission and vaccine eﬃcacy were con-
ducted in two separate boxes. In box 1, a group of lla-
mas (n = 3) were intranasally inoculated with a 107
TCID50 dose of MERS-CoV Qatar15/2015 strain (Gen-
Bank Accesion MK280984) in 3 ml saline solution
(1.5 ml in each nostril) using a nebulization device
(LMA® MADgic®, Teleﬂex Inc.). At 2 days post-inocu-
lation (dpi) naïve llamas (n = 5) were put in contact
with infected llamas (Figure 1a, Supplementary Fig.
S1). In box 2, the same protocol as in box 1 was fol-
lowed but using vaccinated llamas (n = 5) as a contact
group (Figure 1b). Each box was set up as in a previous
transmission study performed in pigs [39].
Regarding to the nomenclature used in this study,
animals 1–3 and 4–6 corresponded to intranasally
inoculated llamas in boxes 1 and 2, respectively. Llamas
7–11 were naïve contact animals and llamas 12–16
were immunized contact animals.
Animals were monitored daily for clinical signs
(sneezing, coughing, nasal discharge or dyspnea). Rec-
tal temperatures were recorded with a fast display digi-
tal thermometer (AccuVet®) until day 13 or 15 post-
inoculation (pi) for animals in boxes 1 and 2, respect-
ively. For llamas housed in box 1, nasal swabs (NS)
were obtained daily until day 14 pi, while in box 2
NS were collected daily until day 15 pi and two extra
collections were performed on 17 and 19 dpi. Serum
samples were obtained before the ﬁrst and the second
immunizations, prior to challenge, and weekly after
the MERS-CoV challenge. Animals were euthanized
3-weeks after challenge, with an overdose of pentobar-
bital. An extra sampling of NS was performed prior to
necropsy procedures.
Environmental samples
Three diﬀerent types of environmental samples (ES)
were collected to determine viral loads in the boxes
throughout the study (see Supplementary Fig. S1), as
previously described [39]. An air ﬁltering device (Sartor-
ius MD8, Sartorius Stedim) was used for testing one
thousand litres of air during 20 min (50 L/min air
volume) through a gelatine membrane ﬁlter (ES1).
One wall was scrubbed with two swabs (ES2 and ES3)
and a water sample from the drinking point (ES4) was
also obtained. ES were collected daily until 10 dpi.
Figure 1. Schematic diagram of the llama transmission (a) and vaccination (b) experiments. (a) Three llamas (black, LL1-3) were
intranasally inoculated with MERS-CoV (Qatar15/2015) and two days later were brought in contact with ﬁve naïve llamas (grey, LL7-
11). (b) Vaccination, challenge and sampling scheme showing vaccinated llamas (red, n = 5, LL12-16) and directly inoculated llamas
(black, n = 3; LL4-6) used as a transmission challenge model for MERS-CoV. Dpi, days post-inoculation.
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Viral RNA detection by RT-qPCR
Viral RNA in collected samples was detected by RT-
qPCR as previously described [10,39]. Brieﬂy, NS and
ES, except water samples, were transferred into cryo-
tubes containing either 500 µL DMEM (Lonza) or
PBS (Lonza) supplemented with 100 U/ml penicillin
(ThermoFisher Scientiﬁc, Life Technologies) and 100
μg/ml streptomycin (ThermoFisher Scientiﬁc, Life
Technologies), vortexed and stored at −80°C until
use. Water samples were directly frozen at −80°C
instead. Viral RNA from NS and ES was extracted
with a NucleoSpin® RNA virus kit (Macherey-Nagel)
following the manufacturer’s instructions. The RNA
extracts were tested by using the UpE PCR [40]. RT-
qPCR was carried out using AgPath-IDTM One-Step
RT–PCR Reagents (Applied Biosystems, Life Technol-
ogies), and ampliﬁcation was done by using a 7500 Fast
Real-Time PCR System (Applied Biosystems, Life
Technologies) programmed as follows: 10 min at 50°
C, 10 sec at 95°C, and 45 cycles of 15 s at 95°C and
30 sec at 58°C. Samples with a quantiﬁcation cycle
(Cq) value ≤40 were considered positive for MERS-
CoV RNA. To test for viral replication, viral RNA
extracted form NS was tested for the presence of M
mRNA according to the previously published protocol
by Coleman et al. [41]
Viral RNA sequencing
Viral RNA was extracted from llama NS using the
QIAamp viral RNA mini kit (Qiagen) according to
the manufacturer’s instructions. cDNA was produced
from RNA using Superscript III ﬁrst strand synthesis
system (Invitrogen Corp) using random hexamers.
The cDNA was then used as a template to PCR amplify
the MERS-CoV spike S1 encoding region (nucleotides
positions 21,304–25,660, GenBank Accession
JX869059) using the PfuUltra II Fusion HS DNA poly-
merase (Aligent Technologies). The PCR was carried
out as follows: 95°C for 5 min, 39 cycles of 20 sec at
95°C, 20 sec at 48°C, and 45 sec at 72°C, and a ﬁnal
extension at 72°C for 1 min. The amplicons were
sequenced bidirectionally using the BigDye Terminator
v3.1 cycle sequencing kit on an ABI PRISM 3130XL
Genetic analyzer (Applied Biosystems).
Virus titration
NS and ES collected at diﬀerent times pi were evaluated
for the presence of infectious virus by titration in Vero
cells, as previously reported [10,19]. Ten-fold dilutions
were done, starting with a dilution of 1:10, and
dilutions were transferred to Vero cells. Plates were
daily monitored under the light microscope and wells
were evaluated for the presence of CPE at 5 dpi. The
amount of infectious virus in swabs was calculated by
determining the TCID50.
MERS-CoV S1-ELISA
Speciﬁc S1-antibodies in serum samples from all col-
lected time-points and from all animals were deter-
mined by a MERS-CoV S1-ELISA as previously
described [10,19]. Brieﬂy, 96-well high-binding plates
(Sigma-Aldrich) were coated with 100 µl of S1 protein
[42] at 1 µg/ml in PBS o/n at 4°C. After blocking with
1% bovine serum albumin/PBS/0.5% Tween20 for 1 h
at 37°C, serum samples were tested at a 1:100 dilution,
followed by 1 h incubation at 37°C. Plates were washed
4 times with PBS, and wells were incubated with a goat
anti-llama biotin conjugate (Abcore, 1:1,000 diluted in
blocking buﬀer), followed by incubation with streptavi-
din peroxidase (Sigma-Aldrich). After 1 h of incu-
bation at 37°C, wells were washed 4 times with PBS,
and a TMB substrate solution (Sigma-Aldrich) was
added and allowed to develop for 8–10 min at room
temperature, protected from light. Optical density
was measured at 450 nm.
MERS-CoV N-LIPS
We tested llama sera for MERS-CoV nucleocapsid (N)
speciﬁc antibody responses using a luciferase immuno-
precipitation (LIPS) assay [43]. The N protein was
expressed as an N-terminal Renilla luciferase (Ruc)-
tagged protein (Ruc-N) using pREN2 expression vec-
tor. The cells were lysed, and the luminescence units
(LU)/μl was measured in cell lysates. LIPS assay was
done according to a previous protocol with minor
modiﬁcations [44]. Brieﬂy, serum samples were diluted
1:100 and mixed with 1× 107 LU of Ruc-N in a total
volume of 100 μl in buﬀer A (20 mM Tris, pH 7.5,
150 mM NaCl, 5 mM MgCl2, 1% Triton X-100). The
mixture was incubated on a rotary shaker for 1 h at
room temperature. Then, the mixture was transferred
into MultiScreenHTS BV Filter Plate (Merk Millipore)
containing 5 μl of a 30% suspension of UltraLink
protein A/G beads and further incubated for one
hour. The wells were then washed and luminescence
was measured for each well after adding 100 μl of 0.1
μM coelenterazine (Nanolight Technology) in assay
buﬀer (50 mM potassium phosphate, pH 7.4,
500 mM NaCl, 1 mM EDTA). The sera were tested in
duplicates in at least two independent assays and the
data was averaged to determine the LU value for each
sample.
Hemagglutination inhibition (HI) assay
To test llama sera from the vaccine eﬃcacy study for
functional antibodies against the sialic acid binding
S1 N-terminal domain (S1A), a nanoparticle-based HI
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assay was used. S1A lumazine synthase (LS) nanoparti-
cles were produced as described previously [17,45].
Two-fold diluted sera were mixed with 4 HA units of
S1A-LS and incubated for 30 min at 37°C. Following
incubation, 0.5% washed turkey RBCs were added
and further incubated for 1 h at 4°C. HI titres were
determined as the reciprocal of highest serum dilution
showing inhibition of hemagglutination.
Receptor binding inhibition (RBI) assay
We tested llama sera from the vaccine eﬃcacy study for
antibodies able to block MERS-CoV binding to its
receptor (DPP4) using a competitive ELISA. ELISA
plates were coated with 2 μg/ml recombinant soluble
DPP4 protein [13] overnight at 4°C. The plates were
washed with PBS and blocked with 1% BSA in PBS/
0.1% Tween-20 at 37°C for 1 h. Serum samples were
tested at a 1:20 dilution. Recombinant MERS-CoV
S1-mFc was mixed with diluted sera, incubated for 1
hr at 37°C, added to the plate and further incubated
for 1 h. The plates were then washed and HRP-labelled
rabbit anti-mouse Igs was added to detect S1 bound to
DPP4. Following 1 h of incubation, the plates were
washed and the signal was detected using TMB as
described above. Optical density was measured at 450
nm.
Plaque reduction neutralization assay
Serum samples and nasal swabs were further tested for
neutralizing antibodies against MERS-CoV (Qatar15/
2015 and EMC/2012 isolates) using a plaque reduction
neutralization (PRNT) assay. PRNT assay was carried
out using according to the previously published proto-
col [19] with some modiﬁcation. Brieﬂy, samples were
ﬁrst inactivated at 56°C for 30 min. Then, 50 μl of 2-
fold serial dilutions of heat-inactivated serum were
mixed 1:1 with virus (400 PFU) prior to over-layering
onto Huh7 cells. After 8 h of infection, the cells were
ﬁxed and stained using mouse anti-MERS-CoV
nucleocapsid protein (SinoBiological) and HRP-conju-
gated goat anti-mouse IgG1 (SouthernBiotech). The
number of infected cells were detected using a precipi-
tate-forming TMB substrate (True Blue, KPL) and
counted using an ImmunoSpot® Image analyser (CTL
Europe GmbH). The PRNT titre was calculated based
on a 50% or greater reduction in infected cells counts.
Results
Clinical signs
Three out of the six directly-inoculated and one out of
the ﬁve contact naïve llamas showed moderate nasal
mucus secretion at 8–15 dpi (see Supplementary Fig.
S2). No clinical signs were noticed in any of the ﬁve
vaccinated llamas throughout the study. Despite higher
basal body temperatures, no animals housed in box 1
(inoculated and non-vaccinated in-contact llamas)
showed a signiﬁcant increase in body temperatures
above 40°C upon MERS-CoV challenge. In box 2
(inoculated and vaccinated in-contact llamas), body
temperatures in llamas remained constant all along
the experiment and never exceeded 39.5°C.
MERS-CoV RNA and infectious virus
All MERS-CoV inoculated llamas shed viral RNA in
the nasal cavity during a 2-week period (Figure 2a,
b). The amount of viral RNA was still high (Cq values
< 25) in all inoculated llamas at 6-7 dpi, but a decrease
in RNA load was observed from 8 dpi onwards. In-
contact naïve llamas from box 1 revealed evidence of
infection (detectable viral RNA) 4–5 days after contact,
with viral RNA loads and duration of shedding similar
to those of the inoculated animals (Figure 2a). In box 2,
only one out of the ﬁve vaccinated llamas (No. 15) had
viral RNA in the nasal cavity to levels comparable to
non-vaccinated in-contact animals, while the other
four animals had very low levels of viral RNA (Figure
2b). Additionally, the viral RNA from this llama was
sequenced at days 9–12 pi and used for comparative
analysis of the S1 protein (see Supplementary Fig.
S3). A substitution of serine for phenylalanine was
found at the amino acid position 465 (S465F) in com-
parison with the inoculum isolate S1 protein (see Sup-
plementary Fig. S3a). This mutation was also found in
another vaccinated llama (No. 13) at 10 dpi. Interest-
ingly, we identiﬁed the S465F mutation arising at 5-
6 dpi in three directly inoculated llamas (No.1, 4, 5).
Furthermore, the naïve contact animals were also
investigated and the same mutation was found in
llama No. 9 at 10 dpi (see Supplementary Fig. S3b).
To ensure that this mutant is not a neutralization
escape mutant, the mutant virus was plaque-puriﬁed
form the nasal swab of llama No. 4 at 6 dpi. The
virus was sequenced (Llama-passaged-Qatar15; Gen-
Bank Accession MN507638) to ensure no other
mutations were present in the spike protein and then
used to carry out neutralization assays. The virus was
neutralized by serum of all ﬁve vaccinated animals
(Supplementary Fig. S4a).
RT-qPCR positive nasal swab samples were tested
for the presence of infectious virus. All intranasally
inoculated llamas excreted infectious MERS-CoV at
some point until 8 dpi (Figure 2c, d). The duration of
infectious virus shedding varied among individual ani-
mals ranging from 1 up to 6 consecutive days. In each
box, at least one inoculated llama (animals No. 2 and 5)
shed infectious virus continuously from days 1–6 pi
(Figure 2c, d). Three out of the ﬁve direct contact
naïve llamas from box 1 shed infectious virus at 8, 9
and 10 dpi (Figure 2c). These non-vaccinated in-
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contact animals (No. 7, 9 and 10) exhibited virus titres
at least equal to those observed in inoculated llamas
(Figure 2c, d). The peaks of viral RNA coincided with
the highest levels of infectious virus shed. Although
llama No. 15 had MERS-CoV mRNA indicative of
replication in the nasal cavity to levels comparable to
non-vaccinated in-contact animals (Supplementary
Fig. S5), as assessed by the speciﬁc RT-qPCR described
by Coleman and collaborators [41], none of the
vaccinated animals from box 2 (including llama No.
15) shed infectious virus at any point in the study
(Figure 2d),
Llama No. 7 showed low levels of MERS-CoV RNA
at 1 dpi before in-contact challenge (Figure 2a). How-
ever, this animal remained negative to RT-qPCR
until 5 dpi, suggesting that a contamination occurred
during the collection or the processing of this sample.
Additionally, no infectious virus was detected in this
animal at 1 dpi (Figure 2c).
Relatively low levels of viral RNA were detected in
all types of environmental samples that were taken in
the boxes during the experiment (≥30 Cq) (Table 1).
The highest MERS-CoV RNA levels were found in
drinking water samples. However, titration of infec-
tious virus was not successful.
Humoral immune response
We evaluated the MERS-CoV speciﬁc antibody
responses induced in llamas following infection and
Figure 2. Viral shedding in llamas after experimental inoculation or contact with MERS-CoV-infected llamas. Viral RNA detected in
nasal swab samples collected from naïve (a) and S1 vaccinated (b) llamas at diﬀerent time points after contact with directly inocu-
lated animals. Panels c) and d) display infectious MERS-CoV in nasal swab samples collected from naïve (c) and S1 vaccinated ani-
mals (d) at diﬀerent time points after inoculation. Each line/bar represents an individual animal. Orange lines/bars indicate
experimentally inoculated llamas. Blue and green lines/bars indicate in-contact naïve animals, while purple lines/bars indicate vac-
cinated llamas. Dashed lines depict the detection limit of the assays. Cq, quantiﬁcation cycle; MERS-CoV, Middle East respiratory
syndrome coronavirus; TCID50, 50% tissue culture infective dose.
Table 1.MERS-CoV RNA detection in environmental samples expressed in Cq values at diﬀerent times after inoculation. Swab 1 and
2 correspond to ES2 and ES3 of the Suppl. Fig. S1, respectively. Cq, quantiﬁcation cycle; MERS-CoV, Middle East respiratory
syndrome coronavirus; nc, non-collected samples.
Days post-inoculation 0 1 2 3 4 5 6 7 8 9 10
Box 1 – transmission study
Sartorius − − 35,04 − 36,22 39,43 38,52 nc 38,21 38,72 31,91
Swab 1 − − − − 36,57 − 39,53 nc 32,23 39,64 38,01
Swab 2 − 39,90 − 38,31 35,85 35,35 37,00 nc 34,30 38,12 36,58
Water − 36,31 − − − − 36,01 nc 38,70 33,42 33,24
Box 2 – vaccine trial
Sartorius − − − − − − − 36,79 38,54 − −
Swab 1 − − − − 36,42 − 39,09 37,88 37,34 30,93 34,01
Swab 2 − − − 36,76 − 37,20 − 37,63 − 31,40 35,99
Water − − − 37,89 35,20 30,92 31,91 33,94 34,62 38,77 37,52
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vaccination. Regarding the transmission study, all
directly inoculated and in-contact naïve llamas sero-
converted to MERS-CoV as detected by MERS-CoV
S1 ELISA (Figure 3a) and virus neutralization (Figure
3b). In contrast, only three of those, two directly inocu-
lated and one in-contact, also developed anti-N anti-
body responses (see Supplementary Fig. S6a).
Antibodies against the S1A sialic acid binding domain
were detected in one of the directly inoculated and
four in-contact naïve animals using a HI assay (Figure
3c). Receptor-binding blocking (mainly RBD-directed)
antibodies were detected in the sera of all directly
inoculated animals and in four out of the ﬁve in-con-
tact naïve llama sera using a competitive RBI ELISA
(Figure 3d).
Following MERS-CoV S1 vaccination, all vaccinated
animals (Figure 4a-d, red) developed high titres of
serum S1-reactive antibodies (Figure 4a) and virus neu-
tralizing antibodies against both clade B Qatar15/2015
and a clade A EMC/2102 isolates as detected by PRNT
(Figure 4b, Supplementary Fig. S4b). In particular, the
vaccination induced antibodies against the two func-
tional domains of S1, the S1A binding N-terminal
domain as detected by HI assay (Figure 4c) and the
RBD as detected by a competitive RBI ELISA (Figure
4d). Additionally, only one directly inoculated but
none of the vaccinated animals developed antibodies
against the N protein (Supplementary Fig. S6b). Aim-
ing to assess mucosal immunity elicited upon vacci-
nation, we evaluated the presence of antibodies in the
nasal cavity. Remarkably, we detected low levels of
both MERS-CoV S1-directed and neutralizing
antibodies in the nasal swabs of three out of the ﬁve
vaccinated animals (Figure 4e, f).
Discussion
In this study, experimental MERS-CoV transmission
from infected llamas to naïve in-contact llamas has
been demonstrated for the ﬁrst time. Consistent with
previous studies [10], all MERS-CoV inoculated llamas
got infected, shed infectious virus and were able to
transmit the virus to all naive contact animals as
assessed by MERS-CoV RNA and viral titration of
the nasal swabs. We conﬁrmed that 3 infected llamas
were able to transmit MERS-CoV to at least 5 naïve
animals; nonetheless, further studies are needed to
determine the basic reproduction ratio of this virus
transmission in camelids. Interestingly, the three con-
tact llamas shedding infectious MERS-CoV showed
the highest viral RNA loads, while the remaining two
had higher Cq values and no infectious virus was iso-
lated. Altogether, taking into account that (i) viral
genomic replication was observed in all in-contact
naïve llamas for an extended period, (ii) 3 out of 5
in-contact animals shed detectable infectious virus
and (iii) one of them exhibited nasal discharges, this
in-contact model of virus transmission is valuable to
test vaccine eﬃcacy. However, before stating that lla-
mas can be surrogates of dromedaries for vaccine test-
ing in an in-contact model, it would be important to
assess whether infectious viral pressure elicited by the
experimental challenge are similar between these two
animal species. In that respect, in a previous report,
Figure 3. Serum antibodies elicited against MERS-CoV in inoculated and in-contact naïve llamas. (a) MERS-CoV spike S1, (b) MERS-
CoV neutralizing (Qatar15/2015 strain), (c) hemagglutination inhibition (HI; anti-S1A N-terminal domain), and (d) receptor binding
inhibition (RBI; anti-S1 receptor binding domain) antibodies. The horizontal dotted lines indicate the cutoﬀ of each assay. HI,
hemagglutination inhibition; LL, llama; PRNT, plaque reduction neutralization assay; RBI, receptor binding inhibition; W, week
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two dromedaries inoculated with the MERS-CoV
EMC/2012 strain shed viral RNA and infectious virus
for 13 and 6 days, respectively [19], similar to what
we found in the present study in llamas infected intra-
nasally with the MERS-CoV Qatar15/2015 strain.
Based on the in vivo protective capacity of mono-
clonal antibodies directed against diﬀerent domains
of the spike protein [17], a broader protective immune
response can be achieved using multi-domain vaccines
(S1A and S1B domains) compared to RBD-focused vac-
cines. Thus, the eﬃcacy of an S1 recombinant protein
emulsiﬁed with the adjuvant Montanide™ ISA 206
VG was evaluated as a potential vaccine candidate.
We showed that immunized llamas were eﬃciently
protected against MERS-CoV infection; no infectious
virus was detected in the nose of any of the vaccinated
animals and viral RNA shedding remained low (Cq≥
34), with the exception of one llama (No. 15). Viral
mRNA was also detected in the nasal cavity of this
llama, which might be from intracellular viral mRNA
from cells harvested in the nasal swabs; nonetheless,
we could not detect any infectious virus. Neutralization
of the virus by antibodies at mucosal level may have
inhibited infectious viral particle production. The
lack of detectable infectious virus in the vaccinated lla-
mas despite being infected, renders these animals unli-
kely to transmit the virus further to other animals and
thus blocking the transmission chain. In addition, our
studies revealed a mutation (S465F) in the spike
protein encoded by this viral RNA, which may suggest
a potential escape variant being produced. However,
the emergence of the same mutation in another vacci-
nated llama, in one naïve in-contact animal and in
other three directly inoculated llamas was revealed. In
addition, the capacity of vaccinated animals to induce
NAbs against this variant when isolated, indicate that
it is unlikely an escape variant induced under antibody
pressure. Mutation at this site (S465F) is not directly
involved in receptor binding but has been previously
reported to occur as a result of virus adaptation to its
Figure 4. Antibody responses to MERS-CoV elicited in directly inoculated (LL4-6; black) and in-contact MERS-CoV S1 vaccinated
(LL12-16; red) llamas in sera (a-d) and nasal swabs (e,f). (a,e) MERS-CoV S1-reactive antibodies, (b,f) MERS-CoV neutralizing anti-
bodies (Qatar15/2015 strain), (c) hemagglutination inhibition (HI; anti-S1A N terminal domain) antibodies, and (d) receptor binding
inhibition (RBI; anti-S1 receptor binding domain) antibodies. The horizontal dotted lines indicate the cutoﬀ of each assay. HI,
hemagglutination inhibition; LL, llama; PRNT, plaque reduction neutralization assay; RBI, receptor binding inhibition; W, week
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host receptor [46]. Overall, this indicates a probable
adaptive mutation rather than a vaccine escape
mutation.
Immunization with the S1 protein induced anti-
bodies against the RBD as conﬁrmed by the RBI and
virus neutralization assays as well as antibodies to the
S1A domain as conﬁrmed by HI assay. These latter
antibodies may be important in blocking virus attach-
ment to sialic acid present in camelids, as it has been
demonstrated in the dromedary camel upper respirat-
ory tract [45]. Importantly, serum NAbs were gener-
ated in all vaccinated animals after the boosting
immunization and were maintained during challenge.
Therefore, a correlation of NAb levels in serum upon
vaccination and protection occurred, as previously
described in another vaccination study in camelids
[37]. Notably, we detected mucosal NAb in the nasal
cavity of 3 out of 5 vaccinated llamas, as also reported
in dromedary camels immunized with an MVA-based
candidate [19]. In addition, we demonstrate that vacci-
nation of llamas with a spike protein from a clade A
MERS-CoV (EMC/2012 isolate) provides protection
against a challenge with a clade B virus (Qatar15/
2015 islolate). Since evidence of MERS-CoV reinfec-
tion has been reported in camels in the ﬁeld [47],
further studies to determine whether intramuscular
administration of the subunit vaccine can boost muco-
sal immunity in the upper respiratory tract of animals
that have been previously exposed to MERS-CoV are
needed.
A critical component of a vaccine that inﬂuences the
duration and the quality of immune responses is the
adjuvant. Here we used the Montanide™ ISA 206
VG adjuvant, which was shown to induce long-term
protective immunity in large animal species by stimu-
lating both cell-mediated and humoral immune
responses [48]. Further studies should be conducted
in target species in order to determine the optimal anti-
gen dose and the persistence of NAb following S1
recombinant vaccination. In fact, here, two doses of
35 and 50 µg were enough to induce protection, as
opposed to a recent study which used 3 doses of
400 µg of the S1 antigen with a combination of adju-
vants [37]. Unlike vector-based vaccines, protein-
based vaccines do not require safety testing in high
containment facilities and ﬁeld studies could be directly
conducted; thus, reducing the cost of the proposed vac-
cine. The registered adjuvant used in this study, Mon-
tanide™ ISA 206 VG, oﬀers economical and practical
use for ﬁeld applications. Therefore, the S1 recombi-
nant vaccine tested in this study appears as a good can-
didate to prevent animal-to-animal and, eventually,
animal-to-human transmission.
Overall, this work revealed that the llama model can
be a surrogate for dromedary camel in MERS-CoV
transmission and vaccination studies. Moreover,
immunization with the MERS-CoV S1 recombinant
protein, in combination with a commercial adjuvant,
eﬃciently limits infectious viral shedding from vacci-
nated llamas upon exposure to directly inoculated
ones.
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